Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I, 15505-15511 [2019-07460]
Download as PDF
<![CDATA[
khammond on DSKBBV9HB2PROD with RULES
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
hearings may take the form of, but are
not limited to:
(i) Informal meetings in which the
employee and Board representative are
given full opportunity to present
evidence, witnesses, and argument;
(ii) Informal meetings in which the
hearing official interviews the employee
and Board representative; or
(iii) Formal written submissions with
an opportunity for oral presentation.
(4) Paper hearing. If the hearing
official determines that an oral hearing
is not necessary, he or she will make the
determination based upon a review of
the formal written record, including any
documentation submitted by the
employee or the Board.
(5) Record. The hearing official shall
maintain a summary record of any
hearing conducted under this section.
(e) Decision on hearing. Unless the
employee requests and the hearing
official grants a delay in the
proceedings, at the earliest practicable
date, but in any event no later than 60
days after the filing of the petition
requesting the hearing, the hearing
official will issue a written decision to
the employee. The decision will state
the Board’s position concerning the
existence and amount of the debt, facts
purporting to evidence the nature and
origin of the alleged debt, the hearing
official’s analysis, findings and
conclusions, in light of the hearing, as
to the employee’s and/or Board’s
grounds, the amount and validity of the
debt as determined by the hearing
official, and the repayment schedule, if
not established by written agreement
between the employee and the Board. If
the hearing official determines that a
debt may not be collected under this
section, but the Board finds that the
debt is still valid, the Board may still
seek collection of the debt through other
means, including but not limited to
offset of other Federal payments.
(f) Deductions under this section. The
method of collection under this section
is salary offset from disposable pay (as
defined in 5 CFR 550.1103), except as
described in this paragraph. The size of
installment deductions shall ordinarily
bear a reasonable relationship to the size
of the debt and the employee’s ability to
pay. However, the amount deducted for
any period under this section may not
exceed 15 percent of disposable pay,
unless the employee has agreed in
writing to the deduction of a greater
amount or a higher deduction has been
ordered by a court under section 124 of
Public Law 97–276 (97 stat. 1195).
Ordinarily, debts must be collected in
one lump sum where possible.
However, if the employee is financially
unable to pay in one lump sum or the
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
amount of the debt exceeds 15 percent
of disposable pay (or other applicable
limitation as provided in this paragraph)
for an officially established pay interval,
collection must be made in installments.
Such installment deductions must be
made over a period not greater than the
anticipated period of active duty or
employment, as the case may be, except
as provided in paragraph (g) of this
section.
(g) Separating or separated
employees. If the employee retires or
resigns or if his or her employment or
period of active duty ends before
collection of the debt is completed,
offset may be performed under 31 U.S.C.
3716 from subsequent payments of any
nature (e.g. final salary payment, lumpsum leave, etc.) due the employee from
the paying agency as of the date of
separation to the extent necessary to
liquidate the debt. Such offset may also
be performed where appropriate against
later payments of any kind due the
former employee from the United States
if the debt cannot be liquidated by offset
from any final payment due the former
employee as of the date of separation.
Nothing in this section shall affect any
limitation on alienation of benefits
administered by the Federal Reserve
System’s Office of Employee Benefits.
(h) Non-waiver and refunds of
payments. An employee’s involuntary
payment of all or any portion of a debt
being collected under 5 U.S.C. 5514
must not be construed as a waiver of
any rights which the employee may
have under 5 U.S.C. 5514 or any other
provision of contract or law, unless
there are statutory or contractual
provisions to the contrary. Any amounts
paid or deducted under this section will
be promptly refunded when a debt is
waived or otherwise found not owing to
the United States (unless expressly
prohibited by statute or regulation), or
the employee’s paying agency is
directed by an administrative or judicial
order to refund amounts deducted from
his or her current pay. Refunds do not
bear interest unless required or
permitted by law or contract.
§ 267.6 Interest, penalties, and
administrative costs.
Except with respect to debts
referenced in 31 U.S.C. 3717(g), the
Board will charge interest, costs, and a
six percent penalty on debts covered by
this regulation in accordance with 31
CFR 901.9. The Board will not impose
interest charges on the portion of the
debt that is paid within 30 days after the
date on which interest began to accrue,
nor impose penalty charges on the
portion of the debt that is paid within
90 days after the date on which penalty
PO 00000
Frm 00005
Fmt 4700
Sfmt 4700
15505
began to accrue. The Board will not
impose any charges during periods
during which collection activity has
been suspended pending any review
provided for in this part if the reviewing
official determines that collection of
such charges is against equity and good
conscience or is not in the best interest
of the United States. The Board may, in
its discretion, also waive interest,
penalties, and cost charges for good
cause shown by the debtor (for example,
the debtor is unable to pay any
significant portion of the debt within a
reasonable period of time, or collection
of these charges will jeopardize
collection of the principal of the debt)
or otherwise as authorized in 31 CFR
901.9(g) and 902.2.
By order of the Board of Governors of the
Federal Reserve System, April 11, 2019.
Ann Misback,
Secretary of the Board.
[FR Doc. 2019–07537 Filed 4–15–19; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA–491]
Schedules of Controlled Substances:
Temporary Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA, and FUB-144 into
Schedule I
Drug Enforcement
Administration, Department of Justice.
ACTION: Temporary amendment;
temporary scheduling order.
AGENCY:
The Acting Administrator of
the Drug Enforcement Administration is
issuing this temporary scheduling order
to schedule the synthetic cannabinoids
(SC), ethyl 2-(1-(5-fluoropentyl)-1Hindazole-3-carboxamido)-3,3dimethylbutanoate (trivial name: 5FEDMB-PINACA); methyl 2-(1-(5fluoropentyl)-1H-indole-3carboxamido)-3,3-dimethylbutanoate
(trivial name: 5F-MDMB-PICA); N(adamantan-1-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (trivial names:
FUB-AKB48; FUB-APINACA; AKB48 N(4-FLUOROBENZYL)); 1-(5fluoropentyl)-N-(2-phenylpropan-2-yl)1H-indazole-3-carboxamide (trivial
names: 5F-CUMYL-PINACA; SGT-25);
and (1-(4-fluorobenzyl)-1H-indol-3yl)(2,2,3,3-tetramethylcyclopropyl)
methanone (trivial name: FUB-144), and
their optical, positional, and geometric
isomers, salts, and salts of isomers in
SUMMARY:
E:\FR\FM\16APR1.SGM
16APR1
15506
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
schedule I. This action is based on a
finding by the Acting Administrator that
the placement of these SCs in schedule
I of the Controlled Substances Act is
necessary to avoid an imminent hazard
to the public safety. As a result of this
order, the regulatory controls and
administrative, civil, and criminal
sanctions applicable to schedule I
controlled substances will be imposed
on persons who handle (manufacture,
distribute, reverse distribute, import,
export, engage in research, conduct
instructional activities or chemical
analysis, or possess), or propose to
handle, 5F-EDMB-PINACA, 5F-MDMBPICA, FUB-AKB48, 5F-CUMYL-PINACA
or FUB-144.
This temporary scheduling order
is effective April 16, 2019, until April
16, 2021. If this order is extended or
made permanent, the DEA will publish
a document in the Federal Register.
DATES:
FOR FURTHER INFORMATION CONTACT:
Lynnette M. Wingert, Diversion Control
Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
khammond on DSKBBV9HB2PROD with RULES
Legal Authority
Section 201 of the Controlled
Substances Act (CSA), 21 U.S.C. 811,
provides the Attorney General with the
authority to temporarily place a
substance in schedule I of the CSA for
two years without regard to the
requirements of 21 U.S.C. 811(b) if he
finds that such action is necessary to
avoid an imminent hazard to the public
safety. 21 U.S.C. 811(h)(1). In addition,
if proceedings to control a substance are
initiated under 21 U.S.C. 811(a)(1), the
Attorney General may extend the
temporary scheduling 1 for up to one
year. 21 U.S.C. 811(h)(2).
Where the necessary findings are
made, a substance may be temporarily
scheduled if it is not listed in any other
schedule under section 202 of the CSA,
21 U.S.C. 812, or if there is no
exemption or approval in effect for the
substance under section 505 of the
Federal Food, Drug, and Cosmetic Act
(FDCA), 21 U.S.C. 355. 21 U.S.C.
811(h)(1). The Attorney General has
delegated scheduling authority under 21
U.S.C. 811 to the Administrator of the
DEA. 28 CFR 0.100.
1 Though DEA has used the term ‘‘final order’’
with respect to temporary scheduling orders in the
past, this document adheres to the statutory
language of 21 U.S.C. 811(h), which refers to a
‘‘temporary scheduling order.’’ No substantive
change is intended.
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
Background
Section 201(h)(4) of the CSA, 21
U.S.C. 811(h)(4), requires the
Administrator to notify the Secretary of
the Department of Health and Human
Services (HHS) of his intention to
temporarily place a substance in
schedule I of the CSA.2 The Acting
Administrator transmitted notice of his
intent to place 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 in schedule I on
a temporary basis to the Assistant
Secretary for Health of HHS by letter
dated August 24, 2018. The Assistant
Secretary responded to this notice by
letter dated September 6, 2018, and
advised that based on a review by the
Food and Drug Administration (FDA),
there are currently no active
investigational new drug applications or
approved new drug applications for 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA or FUB144. The Assistant Secretary also stated
that the HHS has no objection to the
temporary placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in
schedule I of the CSA. The DEA has
taken into consideration the Assistant
Secretary’s comments as required by 21
U.S.C. 811(h)(4). 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 are not currently
listed in any schedule under the CSA,
and no exemptions or approvals are in
effect for 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA or FUB-144 under section 505
of the FDCA, 21 U.S.C. 355. The DEA
has found that the control of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in
schedule I on a temporary basis is
necessary to avoid an imminent hazard
to the public safety, and as required by
21 U.S.C. 811(h)(1)(A), a notice of intent
to temporarily schedule 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 was
published in the Federal Register on
December 28, 2018. 83 FR 67166.
To find that placing a substance
temporarily in schedule I of the CSA is
necessary to avoid an imminent hazard
to the public safety, the Administrator is
required to consider three of the eight
2 As discussed in a memorandum of
understanding entered into by the Food and Drug
Administration (FDA) and the National Institute on
Drug Abuse (NIDA), the FDA acts as the lead agency
within the HHS in carrying out the Secretary’s
scheduling responsibilities under the CSA, with the
concurrence of NIDA. 50 FR 9518, Mar. 8, 1985.
The Secretary of the HHS has delegated to the
Assistant Secretary for Health of the HHS the
authority to make domestic drug scheduling
recommendations. 58 FR 35460, July 1, 1993.
PO 00000
Frm 00006
Fmt 4700
Sfmt 4700
factors set forth in section 201(c) of the
CSA, 21 U.S.C. 811(c): The substance’s
history and current pattern of abuse; the
scope, duration and significance of
abuse; and what, if any, risk there is to
the public health. 21 U.S.C. 811(h)(3).
Consideration of these factors includes
actual abuse, diversion from legitimate
channels, and clandestine importation,
manufacture, or distribution. 21 U.S.C.
811(h)(3).
A substance meeting the statutory
requirements for temporary scheduling
may only be placed in schedule I. 21
U.S.C. 811(h)(1). Substances in schedule
I are those that have a high potential for
abuse, no currently accepted medical
use in treatment in the United States,
and a lack of accepted safety for use
under medical supervision. 21 U.S.C.
812(b)(1).
Available data and information for 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA and FUB144, summarized below, indicate that
these synthetic cannabinoids (SCs) have
a high potential for abuse, no currently
accepted medical use in treatment in the
United States, and a lack of accepted
safety for use under medical
supervision. The DEA’s three-factor
analysis and the Assistant Secretary’s
September 6, 2018 letter are available in
their entirety under the tab ‘‘Supporting
Documents’’ of the public docket of this
action at www.regulations.gov.
Synthetic Cannabinoids
The illicit use of SCs continues to
cause severe adverse effects, overdoses
and deaths in the United States. SCs are
substances synthesized in laboratories
that mimic the biological effects of
delta-9-tetrahydrocannabinol (THC), the
main psychoactive ingredient in
marijuana. SCs were introduced to the
designer drug market in several
European countries as ‘‘herbal incense’’
before the initial encounter in the
United States by U.S. Customs and
Border Protection (CBP) in November
2008. Since 2009, misuse of SCs has
escalated in the United States as
evidenced by large numbers of law
enforcement encounters of SCs applied
onto plant material and in other
designer drug products intended for
human consumption. Recent hospital
reports, scientific publications, and/or
law enforcement reports demonstrate
that 5F-EDMB-PINACA, 5F-MDMBPICA, FUB-AKB48, 5F-CUMYLPINACA, FUB-144 and their associated
designer drug products are being abused
for their psychoactive properties (see
DEA 3-Factor Analysis). As with many
generations of SCs encountered since
2009, the abuse of 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5F-
E:\FR\FM\16APR1.SGM
16APR1
khammond on DSKBBV9HB2PROD with RULES
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
CUMYL-PINACA and FUB-144 is
negatively impacting communities in
the United States.
As noted by the DEA and CBP, SCs
originate from foreign sources, such as
China. Bulk powder substances are
smuggled via common carrier into the
United States and find their way to
clandestine designer drug product
manufacturing operations located in
residential neighborhoods, garages,
warehouses, and other similar
destinations throughout the country.
According to online discussion boards
and law enforcement encounters,
spraying or mixing the SCs with plant
material provides a vehicle for the most
common route of administration—
smoking (using a pipe, a water pipe, or
rolling the drug-laced plant material in
cigarette papers).
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144 have no accepted medical use
in the United States. Use of 5F-MDMBPICA, 5F-EDMB-PINACA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 has
been reported to result in adverse effects
in humans in the United States (see
DEA 3-Factor Analysis). In addition,
there have been multiple law
enforcement seizures of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in
the United States. Use of other SCs has
resulted in signs of addiction and
withdrawal. Based on the
pharmacological similarities between
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144 and other SCs, these five SCs
are likely to produce signs of addiction
and withdrawal similar to those
produced by other SCs.
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144 are SCs that have
pharmacological effects similar to the
schedule I hallucinogen THC, and other
temporarily and permanently controlled
schedule I SCs. In addition, the misuse
of 5F-CUMYL-PINACA, 5F-EDMBPINACA and FUB-144 has been
associated with multiple overdoses
requiring emergency medical
intervention (see DEA 3-Factor
Analysis) while deaths have been
reported that involved FUB-AKB48.
With no approved medical use and
limited safety or toxicological
information, 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 have emerged in
the designer drug market, and the abuse
of these substances for their
psychoactive properties is concerning.
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
Factor 4. History and Current Pattern of
Abuse
SCs have been developed by
researchers over the last 30 years as
tools for investigating the
endocannabinoid system (e.g.,
determining CB1 and CB2 receptor
activity). The first encounter of SCs
intended for illicit use within the
United States occurred in November
2008 by CBP. Since then, the popularity
of SCs as product adulterants and
objects of abuse has increased as
evidenced by law enforcement seizures,
public health information, and media
reports.
Numerous SCs have been identified as
product adulterants, and law
enforcement has seized bulk amounts of
these substances. As successive
generations of SCs have been identified
and controlled as schedule I substances,
illicit distributors have developed new
SC substances that vary only by slight
modifications to their chemical
structure while retaining
pharmacological effects related to their
abuse potential. These substances, and
products laced with these substances,
are marketed under the guise of ‘‘herbal
incense’’ and promoted as a ‘‘legal high’’
with a disclaimer that they are ‘‘not for
human consumption.’’ Thus, after
section 1152 of the Food and Drug
Administration Safety and Innovation
Act (FDASIA), Public Law 112–144,
placed cannabimimetic agents and 26
specific substances (15 of these are SCs)
into schedule I, law enforcement
documented the emergence of new SCs
including UR-144, XLR11, AKB48, PB22, 5F-PB-22, AB-FUBINACA, and ADBPINACA. After these substances were
temporarily scheduled (78 FR 28735,
May 16, 2013; 79 FR 7577, February 10,
2014) other generations of SCs appeared
and were temporarily controlled,
including AB-CHMINACA, ABPINACA, THJ-2201 (80 FR 5042, January
30, 2015), MAB-CHMINACA (81 FR
6171, February 5, 2016), 5F-ADB, 5FAMB, 5F-ABK48, ADB-FUBINACA,
MDMB-CHMICA, MDMB-FUBINACA
(82 FR 17119, April 10, 2017), FUBAMB (82 FR 51154, November 3, 2017)
NM2201, 5F-AB-PINACA, 4-CNCUMYL-BUTINACA, MMB-CHMICA
and 5F-CUMYL-P7AICA (83 FR 31877,
July 10, 2018).
FUB-AKB48 was first identified in
seized drug evidence in October 2013,
followed by FUB-144 (January 2014),
5F-MDMB-PICA (October 2016), 5FEDMB-PINACA (October 2017) and 5FCUMYL-PINACA (February 2018).
Following their manufacture in China,
SCs are often encountered in countries
including New Zealand, Australia, and
PO 00000
Frm 00007
Fmt 4700
Sfmt 4700
15507
Russia before appearing throughout
Europe, and eventually in the United
States. 5F-CUMYL-PINACA was first
reported in the German and Swiss illicit
drug markets in 2015 but didn’t show
up in the United States until February
2018; 5F-EDMB-PINACA was reported
in China in 2016 but didn’t appear in
the United States until October 2017;
and 5F-MDMB-PICA was reported in
Germany in August 2016 and November
2016 in Belgium, a few months before
showing up in the United States. These
data further support that based upon
trends, SCs appear in the illicit drug
markets of other countries including
those in Europe, often before being
trafficked in the United States. The
misuse of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 has been
associated with law enforcement
seizures, overdoses requiring emergency
medical intervention, or both (see DEA
3-Factor Analysis).
The powder form of SCs is typically
dissolved in solvents (e.g., acetone)
before being applied to plant material,
or dissolved in a propellant intended for
use in electronic cigarette devices. In
addition, 5F-EDMB-PINACA was
identified as an adulterant on pieces of
paper that were smuggled into a
detention facility and later found
partially burned (see DEA 3—Factor
Analysis). Law enforcement personnel
have encountered various application
methods including buckets or cement
mixers in which plant material and one
or more SCs are mixed together, or in
large areas where the plant material is
spread out so that a dissolved SC
mixture can be applied directly. Once
mixed, the SC plant material is then
allowed to dry before manufacturers
package the product for distribution,
ignoring any control mechanisms to
prevent contamination or to ensure a
uniform concentration of the substance
in each package. Adverse health
consequences may also occur from
directly ingesting the drug during the
manufacturing process. The failure to
adhere to any manufacturing standards
with regard to amounts, the substance(s)
included, purity, or contamination may
increase the risk of adverse events.
However, it is important to note that
adherence to manufacturing standards
would not eliminate their potential to
produce adverse effects because the
toxicity and safety profile of these SCs
have not been studied.
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144, similar to other SCs, have
been found in powder form or mixed
with dried leaves or herbal blends are
marketed under the guise of ‘‘herbal
E:\FR\FM\16APR1.SGM
16APR1
15508
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
incense’’ and promoted as ‘‘legal high’’
with disclaimer that they are ‘‘not for
human consumption.’’ Presentations at
emergency departments directly linked
to the abuse of 5F-EDMB-PINACA and
FUB-144 have included seizures,
agitation, vomiting, tachycardia and
elevated blood pressure (see DEA 3Factor Analysis).
Factor 5. Scope, Duration and
Significance of Abuse
khammond on DSKBBV9HB2PROD with RULES
SCs continue to be encountered in the
illicit market despite scheduling actions
that attempt to safeguard the public
from the adverse effects and safety
issues associated with these substances
(see DEA 3-Factor Analysis). Novel
substances continue to be encountered,
differing only by small chemical
structural modifications intended to
avoid prosecution while maintaining
the pharmacological effects. Law
enforcement and health care
professionals continue to report the
abuse of these substances and their
associated products.
As described by NIDA, many
substances being encountered in the
illicit market, specifically SCs, have
been available for years but have
reentered the marketplace due to a
renewed popularity. The threat of
serious injury to the individual and the
imminent threat to public safety
following the ingestion of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 and
other SCs persist.
Full reports of information obtained
through STARLiMS,3 STRIDE,4 and
NFLIS 5 for the past five years may be
found in the DEA 3-Factor Analysis.
According to NFLIS, STARLiMS and
STRIDE data, forensic laboratories have
detected the following information
about the SCs in question:
• 5F-EDMB-PINACA was identified
in 366 different NFLIS reports from
eight states, since 2017 6 and 22
STRIDE/STARLiMS reports from two
states, since 2017.
3 STARLiMS is a laboratory information
management system that systematically collects
results from drug chemistry analyses conducted by
DEA laboratories. On October 1, 2014, STARLiMS
replaced System to Retrieve Information from Drug
Evidence (STRIDE) as the DEA laboratory drug
evidence data system of record.
4 STRIDE is a database of drug exhibits sent to
DEA laboratories for analysis. Exhibits from the
database are from the DEA, other federal agencies,
and some local law enforcement agencies.
5 The National Forensic Laboratory Information
System (NFLIS) is a national forensic laboratory
reporting system that systematically collects results
from drug chemistry analyses conducted by State
and local forensic laboratories in the United States.
6 At the time of query, 2018 data were still
reporting.
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
• 5F-MDMB-PICA was identified in
381 NFLIS reports from 22 states, since
2016 and 32 STRIDE/STARLiMS reports
from seven states and the District of
Columbia, since 2017.
• FUB-AKB48 was identified in 362
NFLIS reports from 21 states, since 2014
and 37 STRIDE/STARLiMS reports from
eight states, since 2014.
• 5F-CUMYL-PINACA was identified
in 54 NFLIS reports from three states,
since 2018.
• FUB-144 was identified in 403
NFLIS reports from 27 states, since 2014
and 79 STARLiMS reports from 14
states plus Washington, DC, since 2014.
Factor 6. What, if Any, Risk There Is to
the Public Health
Since first being identified in the
United States in 2008, the ingestion of
SCs continues to result in serious
adverse effects. Details of these events
involving 5F-CUMYL-PINACA, 5FEDMB-PINACA, FUB-144, FUB-AKB48
and 5F-MDMB-PICA are summarized
below.
1. In 2015, in London (United
Kingdom), a 34-year-old male was
hospitalized after ingesting a synthetic
cannabinoid product. Toxicological
analysis identified 5F-AKB48 and 5FCUMYL-PINACA in biological samples.
2. In late November and early
December 2015, in Jackson, Mississippi,
five individuals presented at local
emergency facilities following ingestion
of a synthetic cannabinoid-containing
product. Evidence collected from the
individuals tested positive for THC,
MAB-CHMINACA and FUB-144.
Toxicological analysis of biological
samples in all five patients identified
THC, MAB-CHMINACA, and FUB-144.
3. In March 2017, in Chaves, New
Mexico, a 14-year-old female was found
in the bathroom of her home with
seizure-like activity. Following
transport to a local hospital by family
members, she was pronounced dead
approximately 20 minutes later.
Toxicological analysis upon autopsy
identified three SCs: FUB-AKB48, ABCHMINACA, and ADB-CHMINACA
(MAB-CHMINACA). The cause of death
was determined to be toxic effects of
synthetic cannabinoids (FUB-AKB48,
AB-CHMINACA, and ADBCHMINACA).
4. In January 2018, in Pittsburgh,
Pennsylvania, 13 correctional facility
workers were treated for overdose
symptoms including diaphoresis,
hypertension and tachycardia following
ingestion of an airborne substance while
conducting cell searches for contraband.
In response to the overdose events,
evidence retrieved from the searches
tested positive for the synthetic
PO 00000
Frm 00008
Fmt 4700
Sfmt 4700
cannabinoids 5F-ADB, 5F-EDMBPINACA, and 4-CN-CUMYLBUTINACA.
5. In March 2018, in Chicago, Illinois,
a 22-year-old male expired at a local
hospital. Toxicological analysis
confirmed buprenorphine, brodifacoum,
bromadiolone, FUB-AMB and FUBAKB48 in biological samples of this
decedent.
6. In April 2018, in Harrisburg,
Pennsylvania, a 38-year-old male
presented at a local hospital due to
repeated nosebleeds, gastrointestinal
bleeding with anemia and bruising on
his arms. Toxicological analysis
confirmed brodifacoum, FUB-AMB, and
FUB-AKB48 in biological samples.
7. In April 2018, in Harrisburg,
Pennsylvania, another patient presented
at a local hospital due to significant
bleeding and anemia requiring a
transfusion. Toxicological analysis
confirmed brodifacoum, FUB-AMB, and
FUB-AKB48 in biological samples.
8. In June 2018, in Chicago, Illinois,
a 25-year-old male expired at a local
hospital. Toxicological analysis
confirmed brodifacoum, bromadiolone,
FUB-AMB and FUB-AKB48 in
biological samples of this decedent.
9. In July 2018, in Washington, DC, in
excess of 260 overdoses and four deaths
were reported following use of a
synthetic cannabinoid product. Analysis
of drug evidence from the overdose
event confirmed the presence of the
synthetic cannabinoids FUB-AMB,
EMB-FUBINACA and FUB-144.
10. In August 2018, in New Haven,
Connecticut, in excess of 47 overdoses
were reported following the use of a
synthetic cannabinoid product. Analysis
of drug evidence from the overdose
event confirmed the presence of the
synthetic cannabinoids 5F-ADB, FUBAMB and 5F-MDMB-PICA.
11. In September 2018, law
enforcement in Georgia seized multiple
electronic cigarettes with various
colored viscous liquids following the
reports of overdoses. Laboratory
analysis on the seized evidence
determined the substance to be 5FCUMYL-PINACA.
12. From September 10 to 16, 2018, in
Washington, DC, at least 244 overdoses
were reported following use of a
synthetic cannabinoid product. Analysis
of drug evidence from the overdose
event confirmed the presence of the
synthetic cannabinoids FUB-AMB and
5F-MDMB-PICA.
Because they share pharmacological
similarities with schedule I substances
(D9-THC, JWH-018 and other
temporarily and permanently controlled
schedule I SCs), 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYL-
E:\FR\FM\16APR1.SGM
16APR1
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
khammond on DSKBBV9HB2PROD with RULES
PINACA, and FUB-144 pose serious
risks to an abuser. Tolerance to SCs may
develop fairly rapidly with larger doses
being required to achieve the desired
effect. Acute and chronic abuse of SCs
in general have been linked to adverse
health effects including signs of
addiction and withdrawal, numerous
reports of emergency department
admissions, and overall toxicity and
deaths. Psychiatric case reports have
been reported in the scientific literature
detailing the SC abuse and associated
psychoses. As abusers obtain these
drugs through unknown sources, the
identity and purity of these substances
is uncertain and inconsistent, thus
posing significant adverse health risks
to users.
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144 are being encountered on the
illicit drug market and have no accepted
medical use in the United States.
Regardless, these products continue to
be easily available and abused by
diverse populations.
Finding of Necessity of Schedule I
Placement To Avoid Imminent Hazard
to Public Safety
In accordance with 21 U.S.C.
811(h)(3), based on the available data
and information summarized above, the
continued uncontrolled manufacture,
distribution, reverse distribution,
importation, exportation, conduct of
research and chemical analysis,
possession, and abuse of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 pose
an imminent hazard to the public safety.
The DEA is not aware of any currently
accepted medical uses for 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA or FUB-144 in the
United States. A substance meeting the
statutory requirements for temporary
scheduling, 21 U.S.C. 811(h)(1), may
only be placed in schedule I. Substances
in schedule I are those that have a high
potential for abuse, no currently
accepted medical use in treatment in the
United States, and a lack of accepted
safety for use under medical
supervision. Available data and
information for 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 indicate that
these SCs have a high potential for
abuse, no currently accepted medical
use in treatment in the United States,
and a lack of accepted safety for use
under medical supervision. As required
by section 201(h)(4) of the CSA, 21
U.S.C. 811(h)(4), the Acting
Administrator, through a letter dated
August 24, 2018, notified the Assistant
Secretary of the DEA’s intention to
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
temporarily place 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5FCUMYL-PINACA and FUB-144 in
schedule I. A notice of intent was
subsequently published in the Federal
Register on December 28, 2018. 83 FR
67166.
Conclusion
In accordance with the provisions of
section 201(h) of the CSA, 21 U.S.C.
811(h), the Acting Administrator
considered available data and
information, and herein sets forth the
grounds for his determination that it is
necessary to temporarily schedule ethyl
2-(1-(5-fluoropentyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate
(trivial name: 5F-EDMB-PINACA);
methyl 2-(1-(5-fluoropentyl)-1H-indole3-carboxamido)-3,3-dimethylbutanoate
(trivial name: 5F-MDMB-PICA); N(adamantan-1-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (trivial names:
FUB-AKB48; FUB-APINACA; AKB48 N(4-FLUOROBENZYL)); 1-(5fluoropentyl)-N-(2-phenylpropan-2-yl)1H-indazole-3-carboxamide (trivial
names: 5F-CUMYL-PINACA; SGT-25);
and (1-(4-fluorobenzyl)-1H-indol-3yl)(2,2,3,3tetramethylcyclopropyl)methanone
(trivial name: FUB-144) in schedule I of
the CSA to avoid an imminent hazard to
the public safety.
Because the Acting Administrator
hereby finds it necessary to temporarily
place 5F-EDMB-PINACA, 5F-MDMBPICA, FUB-AKB48, 5F-CUMYL-PINACA
and FUB-144 in schedule I to avoid an
imminent hazard to the public safety,
this temporary order scheduling these
substances is effective on the date of
publication in the Federal Register, and
is in effect for a period of two years,
with a possible extension of one
additional year, pending completion of
the regular (permanent) scheduling
process. 21 U.S.C. 811(h)(1) and (2).
The CSA sets forth specific criteria for
scheduling a drug or other substance.
Permanent scheduling actions in
accordance with 21 U.S.C. 811(a) are
subject to formal rulemaking procedures
done ‘‘on the record after opportunity
for a hearing’’ conducted pursuant to
the provisions of 5 U.S.C. 556 and 557.
21 U.S.C. 811. The permanent
scheduling process of formal
rulemaking affords interested parties
with appropriate process and the
government with any additional
relevant information needed to make a
determination. Final decisions that
conclude the permanent scheduling
process of formal rulemaking are subject
to judicial review. 21 U.S.C. 877.
Temporary scheduling orders are not
PO 00000
Frm 00009
Fmt 4700
Sfmt 4700
15509
subject to judicial review. 21 U.S.C.
811(h)(6).
Requirements for Handling
Upon the effective date of this
temporary order, 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5FCUMYL-PINACA and FUB-144 will be
subject to the regulatory controls and
administrative, civil, and criminal
sanctions applicable to the manufacture,
distribution, reverse distribution,
importation, exportation, engagement in
research, and conduct of instructional
activities or chemical analysis with, and
possession of schedule I controlled
substances including the following:
1. Registration. Any person who
handles (manufactures, distributes,
reverse distributes, imports, exports,
engages in research, or conducts
instructional activities or chemical
analysis with, or possesses), or who
desires to handle, 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5FCUMYL-PINACA or FUB-144 must be
registered with the DEA to conduct such
activities pursuant to 21 U.S.C. 822,
823, 957, and 958, and in accordance
with 21 CFR parts 1301 and 1312, as of
April 16, 2019. Any person who
currently handles 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5FCUMYL-PINACA or FUB-144, and is not
registered with the DEA, must submit an
application for registration and may not
continue to handle 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5FCUMYL-PINACA or FUB-144 as of April
16, 2019, unless the DEA has approved
that application for registration
pursuant to 21 U.S.C. 822, 823, 957, and
958, and in accordance with 21 CFR
parts 1301 and 1312. Retail sales of
schedule I controlled substances to the
general public are not allowed under the
CSA. Possession of any quantity of these
substances in a manner not authorized
by the CSA on or after April 16, 2019
is unlawful and those in possession of
any quantity of these substances may be
subject to prosecution pursuant to the
CSA.
2. Disposal of stocks. Any person who
does not desire or is not able to obtain
a schedule I registration to handle 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA or FUB144 must surrender all currently held
quantities of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA or FUB-144.
3. Security. 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 are subject to
schedule I security requirements and
must be handled and stored pursuant to
21 U.S.C. 821, 823, 871(b), and in
E:\FR\FM\16APR1.SGM
16APR1
khammond on DSKBBV9HB2PROD with RULES
15510
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
accordance with 21 CFR 1301.71–
1301.93, as of April 16, 2019.
4. Labeling and Packaging. All labels,
labeling, and packaging for commercial
containers of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA or FUB-144 must be in
compliance with 21 U.S.C. 825, 958(e),
and be in accordance with 21 CFR part
1302. Current DEA registrants shall have
30 calendar days from April 16, 2019, to
comply with all labeling and packaging
requirements.
5. Inventory. Every DEA registrant
who possesses any quantity of 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA or FUB144 on the effective date of this order
must take an inventory of all stocks of
these substances on hand, pursuant to
21 U.S.C. 827 and 958, and in
accordance with 21 CFR 1304.03,
1304.04, and 1304.11. Current DEA
registrants shall have 30 calendar days
from the effective date of this order to
be in compliance with all inventory
requirements. After the initial
inventory, every DEA registrant must
take an inventory of all controlled
substances (including 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144) on
hand on a biennial basis, pursuant to 21
U.S.C. 827 and 958, and in accordance
with 21 CFR 1304.03, 1304.04, and
1304.11.
6. Records. All DEA registrants must
maintain records with respect to 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA and FUB144 pursuant to 21 U.S.C. 827 and
958(e), and in accordance with 21 CFR
parts 1304, 1312, 1317 and § 1307.11.
Current DEA registrants authorized to
handle 5F-EDMB-PINACA, 5F-MDMBPICA, FUB-AKB48, 5F-CUMYL-PINACA
or FUB-144 shall have 30 calendar days
from the effective date of this order to
be in compliance with all recordkeeping
requirements.
7. Reports. All DEA registrants who
manufacture or distribute 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA or FUB-144 must
submit reports pursuant to 21 U.S.C.
827 and in accordance with 21 CFR
1304 and 1312 as of April 16, 2019.
8. Order Forms. All DEA registrants
who distribute 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA or FUB-144 must comply with
order form requirements pursuant to 21
U.S.C. 828 and in accordance with 21
CFR part 1305 as of April 16, 2019.
9. Importation and Exportation. All
importation and exportation of 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA or FUB144 must be in compliance with 21
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
U.S.C. 952, 953, 957, 958, and in
accordance with 21 CFR part 1312 as of
April 16, 2019.
10. Quota. Only DEA registered
manufacturers may manufacture 5FEDMB-PINACA, 5F-MDMB-PICA, FUBAKB48, 5F-CUMYL-PINACA or FUB144 in accordance with a quota assigned
pursuant to 21 U.S.C. 826 and in
accordance with 21 CFR part 1303 as of
April 16, 2019.
11. Liability. Any activity involving
5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA or
FUB-144 not authorized by, or in
violation of the CSA, occurring as of
April 16, 2019, is unlawful, and may
subject the person to administrative,
civil, and/or criminal sanctions.
Regulatory Matters
Section 201(h) of the CSA, 21 U.S.C.
811(h), provides for a temporary
scheduling action where such action is
necessary to avoid an imminent hazard
to the public safety. As provided in this
subsection, the Attorney General may,
by order, schedule a substance in
schedule I on a temporary basis. Such
an order may not be issued before the
expiration of 30 days from (1) the
publication of a notice in the Federal
Register of the intention to issue such
order and the grounds upon which such
order is to be issued, and (2) the date
that notice of the proposed temporary
scheduling order is transmitted to the
Assistant Secretary. 21 U.S.C. 811(h)(1).
Inasmuch as section 201(h) of the
CSA directs that temporary scheduling
actions be issued by order (as distinct
from a rule) and sets forth the
procedures by which such orders are to
be issued, the DEA believes that the
notice and comment requirements of
section 553 of the Administrative
Procedure Act (APA), 5 U.S.C. 553,
which are applicable to rulemaking, do
not apply to this temporary scheduling
order. The specific language chosen by
Congress indicates an intention for the
DEA to proceed through the issuance of
an order instead of proceeding by
rulemaking. Given that Congress
specifically requires the Attorney
General to follow rulemaking
procedures for other kinds of scheduling
actions, see section 201(a) of the CSA,
21 U.S.C. 811(a), it is noteworthy that,
in section 201(h), Congress authorized
the issuance of temporary scheduling
actions by order rather than by rule.
In the alternative, even assuming that
this action might be subject to 5 U.S.C.
553, the Administrator finds that there
is good cause to forgo the notice and
comment requirements of section 553,
as any further delays in the process for
issuance of temporary scheduling orders
PO 00000
Frm 00010
Fmt 4700
Sfmt 4700
would be impracticable and contrary to
the public interest in view of the
manifest urgency to avoid an imminent
hazard to the public safety.
Further, the DEA believes that this
temporary scheduling action is not a
‘‘rule’’ as defined by 5 U.S.C. 601(2),
and, accordingly, is not subject to the
requirements of the Regulatory
Flexibility Act. The requirements for the
preparation of an initial regulatory
flexibility analysis in 5 U.S.C. 603(a) are
not applicable where, as here, the DEA
is not required by the APA or any other
law to publish a general notice of
proposed rulemaking.
Additionally, this action is not a
significant regulatory action as defined
by Executive Order 12866 (Regulatory
Planning and Review), section 3(f), and,
accordingly, this action has not been
reviewed by the Office of Management
and Budget.
This action will not have substantial
direct effects on the States, on the
relationship between the national
government and the States, or on the
distribution of power and
responsibilities among the various
levels of government. Therefore, in
accordance with Executive Order 13132
(Federalism) it is determined that this
action does not have sufficient
federalism implications to warrant the
preparation of a Federalism Assessment.
As noted above, this action is an
order, not a rule. Accordingly, the
Congressional Review Act (CRA) is
inapplicable, as it applies only to rules.
However, if this were a rule, pursuant
to the CRA, ‘‘any rule for which an
agency for good cause finds that notice
and public procedure thereon are
impracticable, unnecessary, or contrary
to the public interest, shall take effect at
such time as the federal agency
promulgating the rule determines.’’ 5
U.S.C. 808(2). It is in the public interest
to schedule these substances
immediately to avoid an imminent
hazard to the public safety. This
temporary scheduling action is taken
pursuant to 21 U.S.C. 811(h), which is
specifically designed to enable the DEA
to act in an expeditious manner to avoid
an imminent hazard to the public safety.
21 U.S.C. 811(h) exempts the temporary
scheduling order from standard notice
and comment rulemaking procedures to
ensure that the process moves swiftly.
For the same reasons that underlie 21
U.S.C. 811(h), that is, the DEA’s need to
move quickly to place these substances
in schedule I because they pose an
imminent hazard to the public safety, it
would be contrary to the public interest
to delay implementation of the
temporary scheduling order. Therefore,
this order shall take effect immediately
E:\FR\FM\16APR1.SGM
16APR1
Federal Register / Vol. 84, No. 73 / Tuesday, April 16, 2019 / Rules and Regulations
upon its publication. The DEA has
submitted a copy of this temporary
order to both Houses of Congress and to
the Comptroller General, although such
filing is not required under the Small
Business Regulatory Enforcement
Fairness Act of 1996 (Congressional
Review Act), 5 U.S.C. 801–808 because,
as noted above, this action is an order,
not a rule.
List of Subjects in 21 CFR Part 1308
Administrative practice and
procedure, Drug traffic control,
Reporting and recordkeeping
requirements.
For the reasons set out above, the DEA
amends 21 CFR part 1308 as follows:
PART 1308—SCHEDULES OF
CONTROLLED SUBSTANCES
15511
Authority: 21 U.S.C. 811, 812, 871(b),
956(b), unless otherwise noted.
2. In § 1308.11, add paragraphs (h)(37)
through (41) to read as follows:
■
§ 1308.11
*
Schedule I.
*
*
(h) * * *
*
*
1. The authority citation for part 1308
continues to read as follows:
■
(37) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric
isomers, salts and salts of isomers (trivial name: 5F-EDMB-PINACA) .......................................................................................
(38) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric
isomers, salts and salts of isomers (trivial name: 5F-MDMB-PICA) ............................................................................................
(39) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts
and salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)) ......................................
(40) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers,
salts and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-25) ...................................................................................
(41) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, its optical, positional, and geometric isomers, salts and salts of isomers (trivial name: FUB-144) .............................................................................................................
Dated: April 5, 2019.
Uttam Dhillon,
Acting Administrator.
material must be received by the Coast
Guard on or before September 23, 2019.
ADDRESSES: You may submit comments
identified by docket number USCG–
2018–0955 using Federal eRulemaking
Portal at https://www.regulations.gov.
See the ‘‘Public Participation and
Request for Comments’’ portion of the
SUPPLEMENTARY INFORMATION section for
further instructions on submitting
comments.
[FR Doc. 2019–07460 Filed 4–15–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
If
you have questions about this
rulemaking, call or email Mr. Doug
Blakemore, Eighth Coast Guard District
Bridge Administrator; telephone (504)
671–2128, email Douglas.A.Blakemore@
uscg.mil.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
33 CFR Part 117
[Docket No. USCG–2018–0955]
RIN 1625–AA09
Drawbridge Operation Regulations;
Belle River, LA
Coast Guard, DHS.
ACTION: Notice of temporary deviation
from regulations; request for comments.
AGENCY:
The Coast Guard is issuing a
temporary deviation to the operating
schedule that regulates the State Route
70 (SR 70), pontoon bridge across the
Belle River mile 23.8, near Pierre Part,
Assumption Parish, Louisiana. This
temporary deviation is needed to collect
and analyze information on vehicle
traffic congestion on SR 70 created
when the drawbridge opens to vessel
traffic and the impact to the reasonable
needs of navigation when the bridge
closes to vessels during periods of high
vehicle traffic. During this temporary
deviation the drawbridge will remain
closed to navigation.
DATES: This deviation is effective from
6 a.m. on May 17, 2019 to 6 a.m. on
August 30, 2019. Comments and related
khammond on DSKBBV9HB2PROD with RULES
SUMMARY:
VerDate Sep<11>2014
16:04 Apr 15, 2019
Jkt 247001
I. Table of Abbreviations
CFR Code of Federal Regulations
DHS Department of Homeland Security
FR Federal Register
LA DOTD Louisiana Department of
Transportation and Development
SR State Route
§ Section
U.S.C. United States Code
II. Background, Purpose and Legal
Basis
LA DOTD has requested to change the
operating requirements for the SR 70
pontoon bridge across the Belle River
mile 23.8, near Pierre Part, Assumption
Parish, Louisiana. This bridge currently
opens on signal, except that from 10
p.m. to 6 a.m. the draw shall open on
signal if at least four hour notice is
given according to 33 CFR 117.424.
LA DOTD requested changing this
bridge operating schedule because
vehicle traffic has become congested
PO 00000
Frm 00011
Fmt 4700
Sfmt 4700
7036
7041
7047
7083
7014
during June, July, and August. This
waterway is heavily used by
recreational vessels during the summer
months.
LA DOTD conducted a field study
that showed that about 80 cars were
delayed approximately 15 minutes each
time the bridge opened to vessel traffic
and that the bridge sometimes opened
as many as 4 times per hour. To
alleviate this congestion LA DOTD has
requested to open the bridge to vessel
traffic on the hour from 6 a.m. to 10
p.m. each day.
This 105-day temporary deviation to
the regulations will allow LA DOTD to
collect additional vehicle traffic data to
measure the impact of bridge closures
on traffic congestion. It will also allow
the Coast Guard to collect data on the
impact of the proposed regulation
change on vessels.
This bridge has a vertical clearance of
zero feet in the closed to vessel traffic
position and unlimited vertical
clearance in the open to vessel traffic
position. In June, July, and August 2017
the bridge opened for vessels 374 times.
During this temporary deviation the
bridge will operate as follows:
From 6 a.m. on June 1, 2019 through
6 p.m. on August 31, 2019 the draw of
the SR 70 pontoon bridge across the
Belle River mile 23.8, near Pierre Part,
Assumption Parish, Louisiana shall
open on signal on the hour from 6 a.m.
to 10 p.m.; and that from 10 p.m. to 6
a.m. the draw shall open on signal if at
least four hour notice is given. The
bridge will open on signal for
emergencies.
The Coast Guard will inform the users
of this waterway through Local and
Broadcast Notice to Mariners of the
E:\FR\FM\16APR1.SGM
16APR1
]]>Agencies
[Federal Register Volume 84, Number 73 (Tuesday, April 16, 2019)]
[Rules and Regulations]
[Pages 15505-15511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07460]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-491]
Schedules of Controlled Substances: Temporary Placement of 5F-
EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into
Schedule I
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Temporary amendment; temporary scheduling order.
-----------------------------------------------------------------------
SUMMARY: The Acting Administrator of the Drug Enforcement
Administration is issuing this temporary scheduling order to schedule
the synthetic cannabinoids (SC), ethyl 2-(1-(5-fluoropentyl)-1H-
indazole-3-carboxamido)-3,3-dimethylbutanoate (trivial name: 5F-EDMB-
PINACA); methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate (trivial name: 5F-MDMB-PICA); N-(adamantan-1-yl)-1-
(4-fluorobenzyl)-1H-indazole-3-carboxamide (trivial names: FUB-AKB48;
FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); 1-(5-fluoropentyl)-N-(2-
phenylpropan-2-yl)-1H-indazole-3-carboxamide (trivial names: 5F-CUMYL-
PINACA; SGT-25); and (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl) methanone (trivial name: FUB-144), and their
optical, positional, and geometric isomers, salts, and salts of isomers
in
[[Page 15506]]
schedule I. This action is based on a finding by the Acting
Administrator that the placement of these SCs in schedule I of the
Controlled Substances Act is necessary to avoid an imminent hazard to
the public safety. As a result of this order, the regulatory controls
and administrative, civil, and criminal sanctions applicable to
schedule I controlled substances will be imposed on persons who handle
(manufacture, distribute, reverse distribute, import, export, engage in
research, conduct instructional activities or chemical analysis, or
possess), or propose to handle, 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-
AKB48, 5F-CUMYL-PINACA or FUB-144.
DATES: This temporary scheduling order is effective April 16, 2019,
until April 16, 2021. If this order is extended or made permanent, the
DEA will publish a document in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Lynnette M. Wingert, Diversion Control
Division, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-
6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
Section 201 of the Controlled Substances Act (CSA), 21 U.S.C. 811,
provides the Attorney General with the authority to temporarily place a
substance in schedule I of the CSA for two years without regard to the
requirements of 21 U.S.C. 811(b) if he finds that such action is
necessary to avoid an imminent hazard to the public safety. 21 U.S.C.
811(h)(1). In addition, if proceedings to control a substance are
initiated under 21 U.S.C. 811(a)(1), the Attorney General may extend
the temporary scheduling \1\ for up to one year. 21 U.S.C. 811(h)(2).
---------------------------------------------------------------------------
\1\ Though DEA has used the term ``final order'' with respect to
temporary scheduling orders in the past, this document adheres to
the statutory language of 21 U.S.C. 811(h), which refers to a
``temporary scheduling order.'' No substantive change is intended.
---------------------------------------------------------------------------
Where the necessary findings are made, a substance may be
temporarily scheduled if it is not listed in any other schedule under
section 202 of the CSA, 21 U.S.C. 812, or if there is no exemption or
approval in effect for the substance under section 505 of the Federal
Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 355. 21 U.S.C.
811(h)(1). The Attorney General has delegated scheduling authority
under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100.
Background
Section 201(h)(4) of the CSA, 21 U.S.C. 811(h)(4), requires the
Administrator to notify the Secretary of the Department of Health and
Human Services (HHS) of his intention to temporarily place a substance
in schedule I of the CSA.\2\ The Acting Administrator transmitted
notice of his intent to place 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in schedule I on a temporary basis to the
Assistant Secretary for Health of HHS by letter dated August 24, 2018.
The Assistant Secretary responded to this notice by letter dated
September 6, 2018, and advised that based on a review by the Food and
Drug Administration (FDA), there are currently no active
investigational new drug applications or approved new drug applications
for 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-
144. The Assistant Secretary also stated that the HHS has no objection
to the temporary placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in schedule I of the CSA. The DEA has taken
into consideration the Assistant Secretary's comments as required by 21
U.S.C. 811(h)(4). 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-
PINACA and FUB-144 are not currently listed in any schedule under the
CSA, and no exemptions or approvals are in effect for 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 under section 505
of the FDCA, 21 U.S.C. 355. The DEA has found that the control of 5F-
EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in
schedule I on a temporary basis is necessary to avoid an imminent
hazard to the public safety, and as required by 21 U.S.C. 811(h)(1)(A),
a notice of intent to temporarily schedule 5F-EDMB-PINACA, 5F-MDMB-
PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 was published in the
Federal Register on December 28, 2018. 83 FR 67166.
---------------------------------------------------------------------------
\2\ As discussed in a memorandum of understanding entered into
by the Food and Drug Administration (FDA) and the National Institute
on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS
in carrying out the Secretary's scheduling responsibilities under
the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The
Secretary of the HHS has delegated to the Assistant Secretary for
Health of the HHS the authority to make domestic drug scheduling
recommendations. 58 FR 35460, July 1, 1993.
---------------------------------------------------------------------------
To find that placing a substance temporarily in schedule I of the
CSA is necessary to avoid an imminent hazard to the public safety, the
Administrator is required to consider three of the eight factors set
forth in section 201(c) of the CSA, 21 U.S.C. 811(c): The substance's
history and current pattern of abuse; the scope, duration and
significance of abuse; and what, if any, risk there is to the public
health. 21 U.S.C. 811(h)(3). Consideration of these factors includes
actual abuse, diversion from legitimate channels, and clandestine
importation, manufacture, or distribution. 21 U.S.C. 811(h)(3).
A substance meeting the statutory requirements for temporary
scheduling may only be placed in schedule I. 21 U.S.C. 811(h)(1).
Substances in schedule I are those that have a high potential for
abuse, no currently accepted medical use in treatment in the United
States, and a lack of accepted safety for use under medical
supervision. 21 U.S.C. 812(b)(1).
Available data and information for 5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA and FUB-144, summarized below, indicate that
these synthetic cannabinoids (SCs) have a high potential for abuse, no
currently accepted medical use in treatment in the United States, and a
lack of accepted safety for use under medical supervision. The DEA's
three-factor analysis and the Assistant Secretary's September 6, 2018
letter are available in their entirety under the tab ``Supporting
Documents'' of the public docket of this action at www.regulations.gov.
Synthetic Cannabinoids
The illicit use of SCs continues to cause severe adverse effects,
overdoses and deaths in the United States. SCs are substances
synthesized in laboratories that mimic the biological effects of delta-
9-tetrahydrocannabinol (THC), the main psychoactive ingredient in
marijuana. SCs were introduced to the designer drug market in several
European countries as ``herbal incense'' before the initial encounter
in the United States by U.S. Customs and Border Protection (CBP) in
November 2008. Since 2009, misuse of SCs has escalated in the United
States as evidenced by large numbers of law enforcement encounters of
SCs applied onto plant material and in other designer drug products
intended for human consumption. Recent hospital reports, scientific
publications, and/or law enforcement reports demonstrate that 5F-EDMB-
PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, FUB-144 and their
associated designer drug products are being abused for their
psychoactive properties (see DEA 3-Factor Analysis). As with many
generations of SCs encountered since 2009, the abuse of 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5F-
[[Page 15507]]
CUMYL-PINACA and FUB-144 is negatively impacting communities in the
United States.
As noted by the DEA and CBP, SCs originate from foreign sources,
such as China. Bulk powder substances are smuggled via common carrier
into the United States and find their way to clandestine designer drug
product manufacturing operations located in residential neighborhoods,
garages, warehouses, and other similar destinations throughout the
country. According to online discussion boards and law enforcement
encounters, spraying or mixing the SCs with plant material provides a
vehicle for the most common route of administration--smoking (using a
pipe, a water pipe, or rolling the drug-laced plant material in
cigarette papers).
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-
144 have no accepted medical use in the United States. Use of 5F-MDMB-
PICA, 5F-EDMB-PINACA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 has been
reported to result in adverse effects in humans in the United States
(see DEA 3-Factor Analysis). In addition, there have been multiple law
enforcement seizures of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-
CUMYL-PINACA and FUB-144 in the United States. Use of other SCs has
resulted in signs of addiction and withdrawal. Based on the
pharmacological similarities between 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-
AKB48, 5F-CUMYL-PINACA and FUB-144 and other SCs, these five SCs are
likely to produce signs of addiction and withdrawal similar to those
produced by other SCs.
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-
144 are SCs that have pharmacological effects similar to the schedule I
hallucinogen THC, and other temporarily and permanently controlled
schedule I SCs. In addition, the misuse of 5F-CUMYL-PINACA, 5F-EDMB-
PINACA and FUB-144 has been associated with multiple overdoses
requiring emergency medical intervention (see DEA 3-Factor Analysis)
while deaths have been reported that involved FUB-AKB48. With no
approved medical use and limited safety or toxicological information,
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144
have emerged in the designer drug market, and the abuse of these
substances for their psychoactive properties is concerning.
Factor 4. History and Current Pattern of Abuse
SCs have been developed by researchers over the last 30 years as
tools for investigating the endocannabinoid system (e.g., determining
CB1 and CB2 receptor activity). The first encounter of SCs intended for
illicit use within the United States occurred in November 2008 by CBP.
Since then, the popularity of SCs as product adulterants and objects of
abuse has increased as evidenced by law enforcement seizures, public
health information, and media reports.
Numerous SCs have been identified as product adulterants, and law
enforcement has seized bulk amounts of these substances. As successive
generations of SCs have been identified and controlled as schedule I
substances, illicit distributors have developed new SC substances that
vary only by slight modifications to their chemical structure while
retaining pharmacological effects related to their abuse potential.
These substances, and products laced with these substances, are
marketed under the guise of ``herbal incense'' and promoted as a
``legal high'' with a disclaimer that they are ``not for human
consumption.'' Thus, after section 1152 of the Food and Drug
Administration Safety and Innovation Act (FDASIA), Public Law 112-144,
placed cannabimimetic agents and 26 specific substances (15 of these
are SCs) into schedule I, law enforcement documented the emergence of
new SCs including UR-144, XLR11, AKB48, PB-22, 5F-PB-22, AB-FUBINACA,
and ADB-PINACA. After these substances were temporarily scheduled (78
FR 28735, May 16, 2013; 79 FR 7577, February 10, 2014) other
generations of SCs appeared and were temporarily controlled, including
AB-CHMINACA, AB-PINACA, THJ-2201 (80 FR 5042, January 30, 2015), MAB-
CHMINACA (81 FR 6171, February 5, 2016), 5F-ADB, 5F-AMB, 5F-ABK48, ADB-
FUBINACA, MDMB-CHMICA, MDMB-FUBINACA (82 FR 17119, April 10, 2017),
FUB-AMB (82 FR 51154, November 3, 2017) NM2201, 5F-AB-PINACA, 4-CN-
CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA (83 FR 31877, July 10,
2018).
FUB-AKB48 was first identified in seized drug evidence in October
2013, followed by FUB-144 (January 2014), 5F-MDMB-PICA (October 2016),
5F-EDMB-PINACA (October 2017) and 5F-CUMYL-PINACA (February 2018).
Following their manufacture in China, SCs are often encountered in
countries including New Zealand, Australia, and Russia before appearing
throughout Europe, and eventually in the United States. 5F-CUMYL-PINACA
was first reported in the German and Swiss illicit drug markets in 2015
but didn't show up in the United States until February 2018; 5F-EDMB-
PINACA was reported in China in 2016 but didn't appear in the United
States until October 2017; and 5F-MDMB-PICA was reported in Germany in
August 2016 and November 2016 in Belgium, a few months before showing
up in the United States. These data further support that based upon
trends, SCs appear in the illicit drug markets of other countries
including those in Europe, often before being trafficked in the United
States. The misuse of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-
CUMYL-PINACA and FUB-144 has been associated with law enforcement
seizures, overdoses requiring emergency medical intervention, or both
(see DEA 3-Factor Analysis).
The powder form of SCs is typically dissolved in solvents (e.g.,
acetone) before being applied to plant material, or dissolved in a
propellant intended for use in electronic cigarette devices. In
addition, 5F-EDMB-PINACA was identified as an adulterant on pieces of
paper that were smuggled into a detention facility and later found
partially burned (see DEA 3--Factor Analysis). Law enforcement
personnel have encountered various application methods including
buckets or cement mixers in which plant material and one or more SCs
are mixed together, or in large areas where the plant material is
spread out so that a dissolved SC mixture can be applied directly. Once
mixed, the SC plant material is then allowed to dry before
manufacturers package the product for distribution, ignoring any
control mechanisms to prevent contamination or to ensure a uniform
concentration of the substance in each package. Adverse health
consequences may also occur from directly ingesting the drug during the
manufacturing process. The failure to adhere to any manufacturing
standards with regard to amounts, the substance(s) included, purity, or
contamination may increase the risk of adverse events. However, it is
important to note that adherence to manufacturing standards would not
eliminate their potential to produce adverse effects because the
toxicity and safety profile of these SCs have not been studied.
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-
144, similar to other SCs, have been found in powder form or mixed with
dried leaves or herbal blends are marketed under the guise of ``herbal
[[Page 15508]]
incense'' and promoted as ``legal high'' with disclaimer that they are
``not for human consumption.'' Presentations at emergency departments
directly linked to the abuse of 5F-EDMB-PINACA and FUB-144 have
included seizures, agitation, vomiting, tachycardia and elevated blood
pressure (see DEA 3-Factor Analysis).
Factor 5. Scope, Duration and Significance of Abuse
SCs continue to be encountered in the illicit market despite
scheduling actions that attempt to safeguard the public from the
adverse effects and safety issues associated with these substances (see
DEA 3-Factor Analysis). Novel substances continue to be encountered,
differing only by small chemical structural modifications intended to
avoid prosecution while maintaining the pharmacological effects. Law
enforcement and health care professionals continue to report the abuse
of these substances and their associated products.
As described by NIDA, many substances being encountered in the
illicit market, specifically SCs, have been available for years but
have reentered the marketplace due to a renewed popularity. The threat
of serious injury to the individual and the imminent threat to public
safety following the ingestion of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-
AKB48, 5F-CUMYL-PINACA and FUB-144 and other SCs persist.
Full reports of information obtained through STARLiMS,\3\
STRIDE,\4\ and NFLIS \5\ for the past five years may be found in the
DEA 3-Factor Analysis. According to NFLIS, STARLiMS and STRIDE data,
forensic laboratories have detected the following information about the
SCs in question:
---------------------------------------------------------------------------
\3\ STARLiMS is a laboratory information management system that
systematically collects results from drug chemistry analyses
conducted by DEA laboratories. On October 1, 2014, STARLiMS replaced
System to Retrieve Information from Drug Evidence (STRIDE) as the
DEA laboratory drug evidence data system of record.
\4\ STRIDE is a database of drug exhibits sent to DEA
laboratories for analysis. Exhibits from the database are from the
DEA, other federal agencies, and some local law enforcement
agencies.
\5\ The National Forensic Laboratory Information System (NFLIS)
is a national forensic laboratory reporting system that
systematically collects results from drug chemistry analyses
conducted by State and local forensic laboratories in the United
States.
---------------------------------------------------------------------------
5F-EDMB-PINACA was identified in 366 different NFLIS
reports from eight states, since 2017 \6\ and 22 STRIDE/STARLiMS
reports from two states, since 2017.
---------------------------------------------------------------------------
\6\ At the time of query, 2018 data were still reporting.
---------------------------------------------------------------------------
5F-MDMB-PICA was identified in 381 NFLIS reports from 22
states, since 2016 and 32 STRIDE/STARLiMS reports from seven states and
the District of Columbia, since 2017.
FUB-AKB48 was identified in 362 NFLIS reports from 21
states, since 2014 and 37 STRIDE/STARLiMS reports from eight states,
since 2014.
5F-CUMYL-PINACA was identified in 54 NFLIS reports from
three states, since 2018.
FUB-144 was identified in 403 NFLIS reports from 27
states, since 2014 and 79 STARLiMS reports from 14 states plus
Washington, DC, since 2014.
Factor 6. What, if Any, Risk There Is to the Public Health
Since first being identified in the United States in 2008, the
ingestion of SCs continues to result in serious adverse effects.
Details of these events involving 5F-CUMYL-PINACA, 5F-EDMB-PINACA, FUB-
144, FUB-AKB48 and 5F-MDMB-PICA are summarized below.
1. In 2015, in London (United Kingdom), a 34-year-old male was
hospitalized after ingesting a synthetic cannabinoid product.
Toxicological analysis identified 5F-AKB48 and 5F-CUMYL-PINACA in
biological samples.
2. In late November and early December 2015, in Jackson,
Mississippi, five individuals presented at local emergency facilities
following ingestion of a synthetic cannabinoid-containing product.
Evidence collected from the individuals tested positive for THC, MAB-
CHMINACA and FUB-144. Toxicological analysis of biological samples in
all five patients identified THC, MAB-CHMINACA, and FUB-144.
3. In March 2017, in Chaves, New Mexico, a 14-year-old female was
found in the bathroom of her home with seizure-like activity. Following
transport to a local hospital by family members, she was pronounced
dead approximately 20 minutes later. Toxicological analysis upon
autopsy identified three SCs: FUB-AKB48, AB-CHMINACA, and ADB-CHMINACA
(MAB-CHMINACA). The cause of death was determined to be toxic effects
of synthetic cannabinoids (FUB-AKB48, AB-CHMINACA, and ADB-CHMINACA).
4. In January 2018, in Pittsburgh, Pennsylvania, 13 correctional
facility workers were treated for overdose symptoms including
diaphoresis, hypertension and tachycardia following ingestion of an
airborne substance while conducting cell searches for contraband. In
response to the overdose events, evidence retrieved from the searches
tested positive for the synthetic cannabinoids 5F-ADB, 5F-EDMB-PINACA,
and 4-CN-CUMYL-BUTINACA.
5. In March 2018, in Chicago, Illinois, a 22-year-old male expired
at a local hospital. Toxicological analysis confirmed buprenorphine,
brodifacoum, bromadiolone, FUB-AMB and FUB-AKB48 in biological samples
of this decedent.
6. In April 2018, in Harrisburg, Pennsylvania, a 38-year-old male
presented at a local hospital due to repeated nosebleeds,
gastrointestinal bleeding with anemia and bruising on his arms.
Toxicological analysis confirmed brodifacoum, FUB-AMB, and FUB-AKB48 in
biological samples.
7. In April 2018, in Harrisburg, Pennsylvania, another patient
presented at a local hospital due to significant bleeding and anemia
requiring a transfusion. Toxicological analysis confirmed brodifacoum,
FUB-AMB, and FUB-AKB48 in biological samples.
8. In June 2018, in Chicago, Illinois, a 25-year-old male expired
at a local hospital. Toxicological analysis confirmed brodifacoum,
bromadiolone, FUB-AMB and FUB-AKB48 in biological samples of this
decedent.
9. In July 2018, in Washington, DC, in excess of 260 overdoses and
four deaths were reported following use of a synthetic cannabinoid
product. Analysis of drug evidence from the overdose event confirmed
the presence of the synthetic cannabinoids FUB-AMB, EMB-FUBINACA and
FUB-144.
10. In August 2018, in New Haven, Connecticut, in excess of 47
overdoses were reported following the use of a synthetic cannabinoid
product. Analysis of drug evidence from the overdose event confirmed
the presence of the synthetic cannabinoids 5F-ADB, FUB-AMB and 5F-MDMB-
PICA.
11. In September 2018, law enforcement in Georgia seized multiple
electronic cigarettes with various colored viscous liquids following
the reports of overdoses. Laboratory analysis on the seized evidence
determined the substance to be 5F-CUMYL-PINACA.
12. From September 10 to 16, 2018, in Washington, DC, at least 244
overdoses were reported following use of a synthetic cannabinoid
product. Analysis of drug evidence from the overdose event confirmed
the presence of the synthetic cannabinoids FUB-AMB and 5F-MDMB-PICA.
Because they share pharmacological similarities with schedule I
substances ([Delta]\9\-THC, JWH-018 and other temporarily and
permanently controlled schedule I SCs), 5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-
[[Page 15509]]
PINACA, and FUB-144 pose serious risks to an abuser. Tolerance to SCs
may develop fairly rapidly with larger doses being required to achieve
the desired effect. Acute and chronic abuse of SCs in general have been
linked to adverse health effects including signs of addiction and
withdrawal, numerous reports of emergency department admissions, and
overall toxicity and deaths. Psychiatric case reports have been
reported in the scientific literature detailing the SC abuse and
associated psychoses. As abusers obtain these drugs through unknown
sources, the identity and purity of these substances is uncertain and
inconsistent, thus posing significant adverse health risks to users.
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-
144 are being encountered on the illicit drug market and have no
accepted medical use in the United States. Regardless, these products
continue to be easily available and abused by diverse populations.
Finding of Necessity of Schedule I Placement To Avoid Imminent Hazard
to Public Safety
In accordance with 21 U.S.C. 811(h)(3), based on the available data
and information summarized above, the continued uncontrolled
manufacture, distribution, reverse distribution, importation,
exportation, conduct of research and chemical analysis, possession, and
abuse of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and
FUB-144 pose an imminent hazard to the public safety. The DEA is not
aware of any currently accepted medical uses for 5F-EDMB-PINACA, 5F-
MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 in the United States.
A substance meeting the statutory requirements for temporary
scheduling, 21 U.S.C. 811(h)(1), may only be placed in schedule I.
Substances in schedule I are those that have a high potential for
abuse, no currently accepted medical use in treatment in the United
States, and a lack of accepted safety for use under medical
supervision. Available data and information for 5F-EDMB-PINACA, 5F-
MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 indicate that these
SCs have a high potential for abuse, no currently accepted medical use
in treatment in the United States, and a lack of accepted safety for
use under medical supervision. As required by section 201(h)(4) of the
CSA, 21 U.S.C. 811(h)(4), the Acting Administrator, through a letter
dated August 24, 2018, notified the Assistant Secretary of the DEA's
intention to temporarily place 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA and FUB-144 in schedule I. A notice of intent was
subsequently published in the Federal Register on December 28, 2018. 83
FR 67166.
Conclusion
In accordance with the provisions of section 201(h) of the CSA, 21
U.S.C. 811(h), the Acting Administrator considered available data and
information, and herein sets forth the grounds for his determination
that it is necessary to temporarily schedule ethyl 2-(1-(5-
fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (trivial
name: 5F-EDMB-PINACA); methyl 2-(1-(5-fluoropentyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate (trivial name: 5F-MDMB-PICA); N-
(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (trivial
names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); 1-(5-
fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
(trivial names: 5F-CUMYL-PINACA; SGT-25); and (1-(4-fluorobenzyl)-1H-
indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (trivial name:
FUB-144) in schedule I of the CSA to avoid an imminent hazard to the
public safety.
Because the Acting Administrator hereby finds it necessary to
temporarily place 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-
PINACA and FUB-144 in schedule I to avoid an imminent hazard to the
public safety, this temporary order scheduling these substances is
effective on the date of publication in the Federal Register, and is in
effect for a period of two years, with a possible extension of one
additional year, pending completion of the regular (permanent)
scheduling process. 21 U.S.C. 811(h)(1) and (2).
The CSA sets forth specific criteria for scheduling a drug or other
substance. Permanent scheduling actions in accordance with 21 U.S.C.
811(a) are subject to formal rulemaking procedures done ``on the record
after opportunity for a hearing'' conducted pursuant to the provisions
of 5 U.S.C. 556 and 557. 21 U.S.C. 811. The permanent scheduling
process of formal rulemaking affords interested parties with
appropriate process and the government with any additional relevant
information needed to make a determination. Final decisions that
conclude the permanent scheduling process of formal rulemaking are
subject to judicial review. 21 U.S.C. 877. Temporary scheduling orders
are not subject to judicial review. 21 U.S.C. 811(h)(6).
Requirements for Handling
Upon the effective date of this temporary order, 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 will be subject to
the regulatory controls and administrative, civil, and criminal
sanctions applicable to the manufacture, distribution, reverse
distribution, importation, exportation, engagement in research, and
conduct of instructional activities or chemical analysis with, and
possession of schedule I controlled substances including the following:
1. Registration. Any person who handles (manufactures, distributes,
reverse distributes, imports, exports, engages in research, or conducts
instructional activities or chemical analysis with, or possesses), or
who desires to handle, 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-
CUMYL-PINACA or FUB-144 must be registered with the DEA to conduct such
activities pursuant to 21 U.S.C. 822, 823, 957, and 958, and in
accordance with 21 CFR parts 1301 and 1312, as of April 16, 2019. Any
person who currently handles 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA or FUB-144, and is not registered with the DEA, must
submit an application for registration and may not continue to handle
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 as
of April 16, 2019, unless the DEA has approved that application for
registration pursuant to 21 U.S.C. 822, 823, 957, and 958, and in
accordance with 21 CFR parts 1301 and 1312. Retail sales of schedule I
controlled substances to the general public are not allowed under the
CSA. Possession of any quantity of these substances in a manner not
authorized by the CSA on or after April 16, 2019 is unlawful and those
in possession of any quantity of these substances may be subject to
prosecution pursuant to the CSA.
2. Disposal of stocks. Any person who does not desire or is not
able to obtain a schedule I registration to handle 5F-EDMB-PINACA, 5F-
MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 must surrender all
currently held quantities of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48,
5F-CUMYL-PINACA or FUB-144.
3. Security. 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-
PINACA and FUB-144 are subject to schedule I security requirements and
must be handled and stored pursuant to 21 U.S.C. 821, 823, 871(b), and
in
[[Page 15510]]
accordance with 21 CFR 1301.71-1301.93, as of April 16, 2019.
4. Labeling and Packaging. All labels, labeling, and packaging for
commercial containers of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-
CUMYL-PINACA or FUB-144 must be in compliance with 21 U.S.C. 825,
958(e), and be in accordance with 21 CFR part 1302. Current DEA
registrants shall have 30 calendar days from April 16, 2019, to comply
with all labeling and packaging requirements.
5. Inventory. Every DEA registrant who possesses any quantity of
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 on
the effective date of this order must take an inventory of all stocks
of these substances on hand, pursuant to 21 U.S.C. 827 and 958, and in
accordance with 21 CFR 1304.03, 1304.04, and 1304.11. Current DEA
registrants shall have 30 calendar days from the effective date of this
order to be in compliance with all inventory requirements. After the
initial inventory, every DEA registrant must take an inventory of all
controlled substances (including 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-
AKB48, 5F-CUMYL-PINACA and FUB-144) on hand on a biennial basis,
pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR
1304.03, 1304.04, and 1304.11.
6. Records. All DEA registrants must maintain records with respect
to 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144
pursuant to 21 U.S.C. 827 and 958(e), and in accordance with 21 CFR
parts 1304, 1312, 1317 and Sec. 1307.11. Current DEA registrants
authorized to handle 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-
PINACA or FUB-144 shall have 30 calendar days from the effective date
of this order to be in compliance with all recordkeeping requirements.
7. Reports. All DEA registrants who manufacture or distribute 5F-
EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 must
submit reports pursuant to 21 U.S.C. 827 and in accordance with 21 CFR
1304 and 1312 as of April 16, 2019.
8. Order Forms. All DEA registrants who distribute 5F-EDMB-PINACA,
5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 must comply with
order form requirements pursuant to 21 U.S.C. 828 and in accordance
with 21 CFR part 1305 as of April 16, 2019.
9. Importation and Exportation. All importation and exportation of
5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144
must be in compliance with 21 U.S.C. 952, 953, 957, 958, and in
accordance with 21 CFR part 1312 as of April 16, 2019.
10. Quota. Only DEA registered manufacturers may manufacture 5F-
EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 in
accordance with a quota assigned pursuant to 21 U.S.C. 826 and in
accordance with 21 CFR part 1303 as of April 16, 2019.
11. Liability. Any activity involving 5F-EDMB-PINACA, 5F-MDMB-PICA,
FUB-AKB48, 5F-CUMYL-PINACA or FUB-144 not authorized by, or in
violation of the CSA, occurring as of April 16, 2019, is unlawful, and
may subject the person to administrative, civil, and/or criminal
sanctions.
Regulatory Matters
Section 201(h) of the CSA, 21 U.S.C. 811(h), provides for a
temporary scheduling action where such action is necessary to avoid an
imminent hazard to the public safety. As provided in this subsection,
the Attorney General may, by order, schedule a substance in schedule I
on a temporary basis. Such an order may not be issued before the
expiration of 30 days from (1) the publication of a notice in the
Federal Register of the intention to issue such order and the grounds
upon which such order is to be issued, and (2) the date that notice of
the proposed temporary scheduling order is transmitted to the Assistant
Secretary. 21 U.S.C. 811(h)(1).
Inasmuch as section 201(h) of the CSA directs that temporary
scheduling actions be issued by order (as distinct from a rule) and
sets forth the procedures by which such orders are to be issued, the
DEA believes that the notice and comment requirements of section 553 of
the Administrative Procedure Act (APA), 5 U.S.C. 553, which are
applicable to rulemaking, do not apply to this temporary scheduling
order. The specific language chosen by Congress indicates an intention
for the DEA to proceed through the issuance of an order instead of
proceeding by rulemaking. Given that Congress specifically requires the
Attorney General to follow rulemaking procedures for other kinds of
scheduling actions, see section 201(a) of the CSA, 21 U.S.C. 811(a), it
is noteworthy that, in section 201(h), Congress authorized the issuance
of temporary scheduling actions by order rather than by rule.
In the alternative, even assuming that this action might be subject
to 5 U.S.C. 553, the Administrator finds that there is good cause to
forgo the notice and comment requirements of section 553, as any
further delays in the process for issuance of temporary scheduling
orders would be impracticable and contrary to the public interest in
view of the manifest urgency to avoid an imminent hazard to the public
safety.
Further, the DEA believes that this temporary scheduling action is
not a ``rule'' as defined by 5 U.S.C. 601(2), and, accordingly, is not
subject to the requirements of the Regulatory Flexibility Act. The
requirements for the preparation of an initial regulatory flexibility
analysis in 5 U.S.C. 603(a) are not applicable where, as here, the DEA
is not required by the APA or any other law to publish a general notice
of proposed rulemaking.
Additionally, this action is not a significant regulatory action as
defined by Executive Order 12866 (Regulatory Planning and Review),
section 3(f), and, accordingly, this action has not been reviewed by
the Office of Management and Budget.
This action will not have substantial direct effects on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government. Therefore, in accordance with Executive Order
13132 (Federalism) it is determined that this action does not have
sufficient federalism implications to warrant the preparation of a
Federalism Assessment.
As noted above, this action is an order, not a rule. Accordingly,
the Congressional Review Act (CRA) is inapplicable, as it applies only
to rules. However, if this were a rule, pursuant to the CRA, ``any rule
for which an agency for good cause finds that notice and public
procedure thereon are impracticable, unnecessary, or contrary to the
public interest, shall take effect at such time as the federal agency
promulgating the rule determines.'' 5 U.S.C. 808(2). It is in the
public interest to schedule these substances immediately to avoid an
imminent hazard to the public safety. This temporary scheduling action
is taken pursuant to 21 U.S.C. 811(h), which is specifically designed
to enable the DEA to act in an expeditious manner to avoid an imminent
hazard to the public safety. 21 U.S.C. 811(h) exempts the temporary
scheduling order from standard notice and comment rulemaking procedures
to ensure that the process moves swiftly. For the same reasons that
underlie 21 U.S.C. 811(h), that is, the DEA's need to move quickly to
place these substances in schedule I because they pose an imminent
hazard to the public safety, it would be contrary to the public
interest to delay implementation of the temporary scheduling order.
Therefore, this order shall take effect immediately
[[Page 15511]]
upon its publication. The DEA has submitted a copy of this temporary
order to both Houses of Congress and to the Comptroller General,
although such filing is not required under the Small Business
Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act),
5 U.S.C. 801-808 because, as noted above, this action is an order, not
a rule.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
For the reasons set out above, the DEA amends 21 CFR part 1308 as
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise
noted.
0
2. In Sec. 1308.11, add paragraphs (h)(37) through (41) to read as
follows:
Sec. 1308.11 Schedule I.
* * * * *
(h) * * *
(37) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 7036
carboxamido)-3,3-dimethylbutanoate, its optical,
positional, and geometric isomers, salts and salts of
isomers (trivial name: 5F-EDMB-PINACA).................
(38) methyl 2-(1-(5-fluoropentyl)-1H-indole-3- 7041
carboxamido)-3,3-dimethylbutanoate, its optical,
positional, and geometric isomers, salts and salts of
isomers (trivial name: 5F-MDMB-PICA)...................
(39) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3- 7047
carboxamide, its optical, positional, and geometric
isomers, salts and salts of isomers (trivial names: FUB-
AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL))..........
(40) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 7083
indazole-3-carboxamide, its optical, positional, and
geometric isomers, salts and salts of isomers (trivial
names: 5F-CUMYL-PINACA; SGT-25)........................
(41) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- 7014
tetramethylcyclopropyl) methanone, its optical,
positional, and geometric isomers, salts and salts of
isomers (trivial name: FUB-144)........................
Dated: April 5, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019-07460 Filed 4-15-19; 8:45 am]
BILLING CODE 4410-09-P
